Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma

Published:2020-04 Issue:1 Volume:157 Page:12-20
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Llaurado Fernandez Marta,Dawson Amy,Kim Hannah,Lam Nicole,Russell Holly,Bruce Maegan,Bittner Madison,Hoenisch Joshua,Scott Stephanie A.,Talhouk Aline,Chiu Derek,Provencher Diane,Nourmoussavi Melica,DiMattia Gabriel,Lee Cheng-Han,Gilks C. Blake,Köbel Martin^ORCID,Carey Mark S.

Funder

Terry Fox Research Institute

British Columbia Cancer Foundation

Canadian Institutes of Health Research

Vancouver General Hospital Foundation

Cancer Research Society

BCCF

University of British Columbia

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference36 articles.

1. Quantification of ER/PR expression in ovarian low-grade serous carcinoma;Escobar;Gynecol. Oncol.,2013

2. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis;Wong;Int. J. Gynecol. Pathol.,2007

3. Hormone receptor expression profile of low-grade serous ovarian cancers;Buttarelli;Gynecol. Oncol.,2017

4. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study;Sieh;Lancet Oncol.,2013

5. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase;Grabowski;Gynecol. Oncol.,2016

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study.;Gynecologic Oncology;2024-11

2. Ocular side effects of anticancer agents used in the treatment of gynecologic cancers;Gynecologic Oncology;2024-09

3. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma;Gynecologic Oncology;2024-07

4. Eosinophilic Cells in Ovarian Borderline Serous Tumors as a Predictor of BRAF Mutation;Cancers;2024-06-25

5. Molecular Surrogate Subtypes of Ovarian and Peritoneal Low-grade Serous Carcinoma;International Journal of Gynecological Pathology;2024-06-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3